Intellia Therapeutics (NTLA) said Wednesday that the first patient has been dosed in a phase 3 study of its investigational NTLA-2002 treatment of hereditary angioedema, a disorder that results in recurrent attacks of severe swelling.
The trial will evaluate the efficacy and safety of NTLA-2002 in 60 adults, with enrollment expected to be completed in H2.
Intellia said it expects to submit a biologics license application next year to support its plans for a US launch in 2027.
The company's shares were up 1.5% in recent trading.
Price: 10.09, Change: +0.15, Percent Change: +1.51
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments